A randomized phase III study comparing gemcitabine monotherapy with observation in patients with resected pancreatic cancer

被引：1
|
作者：
Kosuge, T. [1 ]
Ueno, H. [1 ]
Matsuyama, Y. [2 ]
Yamamoto, J. [3 ]
Nakao, A. [4 ]
Egawa, S. [5 ]
Doi, R. [6 ]
Monden, M. [7 ]
Hatori, T. [8 ]
Tanaka, M. [9 ]
机构：
[1] Natl Canc Ctr, Hepatobiliary & Pancreat Surg Div, Tokyo, Japan
[2] Univ Tokyo, Dept Biostat, Tokyo, Japan
[3] Canc Inst Hosp, Dept Gastrointestinal Surg, Tokyo, Japan
[4] Nagoya Univ, Dept Surg 2, Aichi, Japan
[5] Tohoku Univ, Div Gastroenterol, Sendai, Miyagi 980, Japan
[6] Kyoto Univ, Dept Surg, Kyoto, Japan
[7] Osaka Univ, Dept Surg & Clin Oncol, Osaka, Japan
[8] Tokyo Womens Med Univ, Dept Surg, Tokyo, Japan
[9] Kyushu Univ, Dept Surg & Oncol, Fukuoka 812, Japan
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71007-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3504
引用
收藏
页码：260 / 260
页数：1
相关论文
共 50 条
  • [41] Analysis of prognostic factors in patients with advanced pancreatic cancer: Subgroup analysis of a randomized phase III trial comparing single-agent gemcitabine to the gemcitabine plus cisplatin combination.
    Boeck, S
    Hinke, A
    Wilkowski, R
    Heinemann, V
    Grosshadern, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [42] Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study
    Karasek, P
    Skacel, T
    Kocakova, I
    Bednarik, O
    Petruzelka, L
    Melichar, B
    Bustova, I
    Spurny, V
    Trason, T
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (04) : 581 - 586
  • [43] A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    Oettle, H
    Richards, D
    Ramanathan, RK
    van Laethem, JL
    Peeters, M
    Fuchs, M
    Zimmermann, A
    John, W
    Von Hoff, D
    Arning, M
    Kindler, HL
    ANNALS OF ONCOLOGY, 2005, 16 (10) : 1639 - 1645
  • [44] Adjuvant Gemcitabine and Erlotinib for Resected Pancreatic Cancer
    Bao, P.
    Ramanathan, R. K.
    Moser, A. J.
    Bahary, N.
    Lembersky, B. C.
    Bartlett, D. L.
    Hughes, S. J.
    Lee, K. K.
    Zeh, H. J.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S66 - S66
  • [45] ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.
    Neoptolemos, John P.
    Palmer, Dan
    Ghaneh, Paula
    Valle, Juan W.
    Cunningham, David
    Wadsley, Jonathan
    Meyer, Tim
    Anthoney, Alan
    Glimelius, Bengt
    Falk, Stephen
    Segersvard, Ralf
    Izbicki, Jakob R.
    Middleton, Gary William
    Ross, Paul J.
    Wasan, Harpreet
    Mcdonald, Alec
    Crosby, Tom David Lewis
    Psarelli, Eftychia Eirini
    Hammel, Pascal
    Buchler, Markus W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [46] A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
    Scott, Aaron James
    O'Neil, Bert H.
    Gomes, Christina
    Baranda, Joaquina Celebre
    Cohen, Steven J.
    Tejani, Mohamedtaki Abdulaziz
    Maguire, Robert T.
    Wilhelm, Francois
    Maniar, Manoj
    Cohen, Deirdre Jill
    Ma, Wen Wee
    Aisner, Dara
    Cho, Jonathan K.
    Olowokure, Olugbenga Olanrele
    Coveler, Andrew L.
    Menter, Alex R.
    Rubin, Peter
    Cusnir, Mike
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [47] BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.
    Goncalves, A.
    Viret, F.
    Francois, E.
    Dahan, L.
    Perrier, H.
    Lamy, R.
    Re, D.
    Largillier, R.
    Gasmi, M.
    Tchiknavorian, X.
    Turrini, O.
    Moureau-Zabotto, L.
    Delpero, J.
    Viens, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer
    Kamath, Anil
    Yoo, Dal
    Stuart, Oswald A.
    Bijelic, Lana
    Sugarbaker, Paul H.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2009, 4 (02) : 174 - 179
  • [49] A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
    Theile, Susann
    Johansen, Julia Sidenius
    Nielsen, Dorte Lisbet
    Jensen, Benny Vittrup
    Hansen, Carsten Palnaes
    Hasselby, Jane Preuss
    Eiriksson, Sverrir Vidalin
    Chen, Inna Markovna
    PHARMACEUTICS, 2022, 14 (03)
  • [50] Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study
    Chang, H-J.
    Chiu, Y-F.
    Chen, J-S.
    Li, C-P.
    Ho, C-L.
    Shyr, Y-M.
    Chiou, W-C.
    Yeh, C-N.
    Hsieh, R-K.
    Lin, Y-L.
    Tien, Y-W.
    Hwang, T-L.
    Shan, Y-S.
    Chen, L-T.
    ANNALS OF ONCOLOGY, 2018, 29
12345